Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center

Mark Ettel, Gabriel Acosta Gonzalez, Shweta Gera, Ogechukwu Eze, Samuel H. Sigal, James S. Park, Ruliang Xu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Drug-induced liver injury (DILI) accounts for approximately 10% of acute hepatitis cases. DILI can arise as idiosyncratic or intrinsic injury from hundreds of drugs, herbals, and nutritional supplements and is essential to recognize as one of the differential diagnoses of hepatitis in a liver biopsy. The purpose of this study is to investigate the frequency and pathological characteristics of DILI related to the variety of hepatotoxic agents. We searched our pathology database for all patients with hepatitis diagnosed on liver biopsy from January 2012 to May 2016, and selected patients with a diagnosis of DILI. Electronic medical records were reviewed for patient medication list, history of herbal medicine or supplement use, and pre-biopsy liver function test (LFT) results. Clinical and pathologic correlation was used to determine the causative or related agents for DILI. We then assessed histopathologic features of liver injury and categorized biopsy findings as primarily bile duct injury, lobular/portal hepatitis, or mixed changes. Six hundred four total liver biopsies for hepatitis or liver injury were identified, of which 70 cases (11.6%) carried the diagnosis of DILI confirmed by clinical correlation. The most common etiologies associated with DILI were supplements and herbal products (31.4%), antimicrobials (14.3%), chemotherapeutics (11.4%), antilipidemics (7.1%) and immunomodulatory agents (7.1%). LFT results positively correlated with histological findings. Nutritional/herbal supplements have emerged as one of the major hepatotoxicity agents. DILI can manifest as predominantly hepatitis, bile duct injury or combination. Histological pattern recognition in the liver biopsy may help identify specific hepatotoxic agents causing DILI.

Original languageEnglish (US)
Pages (from-to)92-98
Number of pages7
JournalHuman Pathology
Volume68
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

Chemical and Drug Induced Liver Injury
Hepatitis
Biopsy
Liver
Wounds and Injuries
Liver Function Tests
Bile Ducts
History of Medicine
Herbal Medicine
Electronic Health Records
Differential Diagnosis
Databases
Pathology

Keywords

  • Adverse drug reaction
  • Cholestasis
  • Hepatic necrosis
  • Hepatobiliary disease
  • Hepatotoxicity

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center. / Ettel, Mark; Gonzalez, Gabriel Acosta; Gera, Shweta; Eze, Ogechukwu; Sigal, Samuel H.; Park, James S.; Xu, Ruliang.

In: Human Pathology, Vol. 68, 01.10.2017, p. 92-98.

Research output: Contribution to journalArticle

Ettel, Mark ; Gonzalez, Gabriel Acosta ; Gera, Shweta ; Eze, Ogechukwu ; Sigal, Samuel H. ; Park, James S. ; Xu, Ruliang. / Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center. In: Human Pathology. 2017 ; Vol. 68. pp. 92-98.
@article{0410389f69a247b3a0c36b75dae0d7c6,
title = "Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center",
abstract = "Drug-induced liver injury (DILI) accounts for approximately 10{\%} of acute hepatitis cases. DILI can arise as idiosyncratic or intrinsic injury from hundreds of drugs, herbals, and nutritional supplements and is essential to recognize as one of the differential diagnoses of hepatitis in a liver biopsy. The purpose of this study is to investigate the frequency and pathological characteristics of DILI related to the variety of hepatotoxic agents. We searched our pathology database for all patients with hepatitis diagnosed on liver biopsy from January 2012 to May 2016, and selected patients with a diagnosis of DILI. Electronic medical records were reviewed for patient medication list, history of herbal medicine or supplement use, and pre-biopsy liver function test (LFT) results. Clinical and pathologic correlation was used to determine the causative or related agents for DILI. We then assessed histopathologic features of liver injury and categorized biopsy findings as primarily bile duct injury, lobular/portal hepatitis, or mixed changes. Six hundred four total liver biopsies for hepatitis or liver injury were identified, of which 70 cases (11.6{\%}) carried the diagnosis of DILI confirmed by clinical correlation. The most common etiologies associated with DILI were supplements and herbal products (31.4{\%}), antimicrobials (14.3{\%}), chemotherapeutics (11.4{\%}), antilipidemics (7.1{\%}) and immunomodulatory agents (7.1{\%}). LFT results positively correlated with histological findings. Nutritional/herbal supplements have emerged as one of the major hepatotoxicity agents. DILI can manifest as predominantly hepatitis, bile duct injury or combination. Histological pattern recognition in the liver biopsy may help identify specific hepatotoxic agents causing DILI.",
keywords = "Adverse drug reaction, Cholestasis, Hepatic necrosis, Hepatobiliary disease, Hepatotoxicity",
author = "Mark Ettel and Gonzalez, {Gabriel Acosta} and Shweta Gera and Ogechukwu Eze and Sigal, {Samuel H.} and Park, {James S.} and Ruliang Xu",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.humpath.2017.08.029",
language = "English (US)",
volume = "68",
pages = "92--98",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center

AU - Ettel, Mark

AU - Gonzalez, Gabriel Acosta

AU - Gera, Shweta

AU - Eze, Ogechukwu

AU - Sigal, Samuel H.

AU - Park, James S.

AU - Xu, Ruliang

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Drug-induced liver injury (DILI) accounts for approximately 10% of acute hepatitis cases. DILI can arise as idiosyncratic or intrinsic injury from hundreds of drugs, herbals, and nutritional supplements and is essential to recognize as one of the differential diagnoses of hepatitis in a liver biopsy. The purpose of this study is to investigate the frequency and pathological characteristics of DILI related to the variety of hepatotoxic agents. We searched our pathology database for all patients with hepatitis diagnosed on liver biopsy from January 2012 to May 2016, and selected patients with a diagnosis of DILI. Electronic medical records were reviewed for patient medication list, history of herbal medicine or supplement use, and pre-biopsy liver function test (LFT) results. Clinical and pathologic correlation was used to determine the causative or related agents for DILI. We then assessed histopathologic features of liver injury and categorized biopsy findings as primarily bile duct injury, lobular/portal hepatitis, or mixed changes. Six hundred four total liver biopsies for hepatitis or liver injury were identified, of which 70 cases (11.6%) carried the diagnosis of DILI confirmed by clinical correlation. The most common etiologies associated with DILI were supplements and herbal products (31.4%), antimicrobials (14.3%), chemotherapeutics (11.4%), antilipidemics (7.1%) and immunomodulatory agents (7.1%). LFT results positively correlated with histological findings. Nutritional/herbal supplements have emerged as one of the major hepatotoxicity agents. DILI can manifest as predominantly hepatitis, bile duct injury or combination. Histological pattern recognition in the liver biopsy may help identify specific hepatotoxic agents causing DILI.

AB - Drug-induced liver injury (DILI) accounts for approximately 10% of acute hepatitis cases. DILI can arise as idiosyncratic or intrinsic injury from hundreds of drugs, herbals, and nutritional supplements and is essential to recognize as one of the differential diagnoses of hepatitis in a liver biopsy. The purpose of this study is to investigate the frequency and pathological characteristics of DILI related to the variety of hepatotoxic agents. We searched our pathology database for all patients with hepatitis diagnosed on liver biopsy from January 2012 to May 2016, and selected patients with a diagnosis of DILI. Electronic medical records were reviewed for patient medication list, history of herbal medicine or supplement use, and pre-biopsy liver function test (LFT) results. Clinical and pathologic correlation was used to determine the causative or related agents for DILI. We then assessed histopathologic features of liver injury and categorized biopsy findings as primarily bile duct injury, lobular/portal hepatitis, or mixed changes. Six hundred four total liver biopsies for hepatitis or liver injury were identified, of which 70 cases (11.6%) carried the diagnosis of DILI confirmed by clinical correlation. The most common etiologies associated with DILI were supplements and herbal products (31.4%), antimicrobials (14.3%), chemotherapeutics (11.4%), antilipidemics (7.1%) and immunomodulatory agents (7.1%). LFT results positively correlated with histological findings. Nutritional/herbal supplements have emerged as one of the major hepatotoxicity agents. DILI can manifest as predominantly hepatitis, bile duct injury or combination. Histological pattern recognition in the liver biopsy may help identify specific hepatotoxic agents causing DILI.

KW - Adverse drug reaction

KW - Cholestasis

KW - Hepatic necrosis

KW - Hepatobiliary disease

KW - Hepatotoxicity

UR - http://www.scopus.com/inward/record.url?scp=85030851530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030851530&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2017.08.029

DO - 10.1016/j.humpath.2017.08.029

M3 - Article

C2 - 28873351

AN - SCOPUS:85030851530

VL - 68

SP - 92

EP - 98

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -